Results 121 to 130 of about 3,351 (178)

Zanubrutinib plus salvage chemotherapy in patients with refractory/relapsed diffuse large B-cell lymphoma non-candidate for autologous stem cell transplantation: A retrospective study. [PDF]

Ann Hematol
He S, Sun J, Zhong D, Rong C, Liao C, Tan X.   +5 more
europepmc   +1 more source

TP53-aberrated CLL: is BTK inhibitor monotherapy enough? [PDF]

Blood Adv
Niemann CU.
europepmc   +1 more source

Zanubrutinib in the treatment of Waldenström Macroglobulinemia. [PDF]

Future Oncol
Goodall E, Opat S.
europepmc   +1 more source

Treatment outcomes of zanubrutinib-based regimen in newly diagnosed patients with MYC/BCL2 double-expressor diffuse large B-cell lymphoma: a retrospective multicenter real-world study. [PDF]

Ann Hematol
Lu B, Wang Y, Jin M, Zhang J, Xu X, Zeng Y, Zhao L, Wang H.   +7 more
europepmc   +1 more source

Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting. [PDF]

Future Oncol
Shah BD, Xue M, Furnback W, Yang K.
europepmc   +1 more source

Zanubrutinib for high-risk Waldenström macroglobulinemia with complex karyotype and hyperleukocytosis: A case report and literature review. [PDF]

SAGE Open Med Case Rep
Chen J, Zhou J, Xu C, Zheng B, He J, Li R.   +5 more
europepmc   +1 more source

Zanubrutinib, lenalidomide and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as initial treatment in non-germinal center B-cell diffuse large B-cell lymphoma: a multi-center phase 2 study by Jiangsu Cooperative Lymphoma Group (JCLG). [PDF]

BMC Med
Xia Y, Miao Y, Qian S, Zhang R, Qin S, Xie X, Li B, Sha Y, Tang H, Jin H, Cao L, Xu W, Fan L, Li J, Shi W, Zhu H.   +15 more
europepmc   +1 more source

Long-term outcomes and treatment patterns in Waldenström macroglobulinemia patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy. [PDF]

Blood Cancer J
Chohan KL, Gensini L, Seif S, Sun X, Feng L, Becnel MR, Gaballa MM, Lee HC, Pasvolsky O, Patel KK, Ye JC, Weber DM, Orlowski RZ, Thomas SK.   +13 more
europepmc   +1 more source

Skin and Soft Tissue Mucormycosis in Patients Receiving Bruton Tyrosine Kinase Inhibitors: Case Report and Literature Review. [PDF]

Open Forum Infect Dis
Aparicio-Minguijón E, López-Muñoz N, Boán J, Pérez-Jacoiste Asín MA, de la Serna J, Pérez-Ayala A, Enguita AB, Rodríguez-Goncer I, Fernández-Ruiz M.   +8 more
europepmc   +1 more source

Uncertainty in Matching-Adjusted Indirect Comparisons Using Real-World Evidence: Evidence Assessment Group Perspective [PDF]

Beyer FR, Inskip A, Johnson EE, Moradi N, Robinson T, Sagoo GS, Thomson K, Uteh CO   +7 more
core   +1 more source